U.S. markets open in 6 hours 43 minutes
  • S&P Futures

    4,118.25
    -6.25 (-0.15%)
     
  • Dow Futures

    32,711.00
    -26.00 (-0.08%)
     
  • Nasdaq Futures

    12,996.50
    -35.00 (-0.27%)
     
  • Russell 2000 Futures

    1,911.00
    -3.60 (-0.19%)
     
  • Crude Oil

    89.47
    -1.03 (-1.14%)
     
  • Gold

    1,804.30
    -8.00 (-0.44%)
     
  • Silver

    20.35
    -0.13 (-0.64%)
     
  • EUR/USD

    1.0212
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    2.7970
    0.0000 (0.00%)
     
  • Vix

    21.77
    +0.48 (+2.25%)
     
  • GBP/USD

    1.2076
    -0.0000 (-0.00%)
     
  • USD/JPY

    135.0180
    -0.0980 (-0.07%)
     
  • BTC-USD

    22,916.26
    -891.96 (-3.75%)
     
  • CMC Crypto 200

    532.11
    -25.24 (-4.53%)
     
  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, February 28, 2022--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its fourth quarter and full-year 2021 financial results on Thursday, March 3, 2022.

In connection with the earnings release, Gossamer’s management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, March 3, 2022, to discuss the Company’s financial results and provide a corporate update.

Conference ID: 2791984
Domestic Dial-in Number: (833) 646-0603
International Dial-in Number: (929) 517-9782
Live Webcast: https://edge.media-server.com/mmc/p/ci4evdm2

A replay of the audio webcast will be available for 30 days on the Investors section of the Company's website, www.gossamerbio.com.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005298/en/

Contacts

For Investors and Media:
Bryan Giraudo, Chief Financial Officer & Chief Operating Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com